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the TME but occurs also within the bone marrow, wherein 
matricellular proteins contribute to the maintenance of spe-
cialized hematopoietic stem cell niches thereby regulating 
their homeostasis as well as the generation and expan-
sion of myeloid cells under both physiological and patho-
logical conditions. Highlighting the commonalities among 
ECM-myeloid cell interactions in bone marrow and TME, 
in this review we present a picture in which myeloid cells 
might sense and respond to ECM modifications, providing 
different ECM-myeloid cell interfaces that may be use-
ful to define prognostic groups and to tailor therapeutic 
interventions.
Keywords Regulatory myeloid suppressor cells · 
SPARC · Tumor microenvironment · Bone marrow niche · 
Extracellular matrix
Abbreviations
AML  Acute myeloid leukemia
BM  Bone marrow
DLBCL  Diffuse large B cell lymphoma
ECM  Extracellular matrix
EMT  Epithelial to mesenchymal transition
HSC  Hematopoietic stem cell
IFNγ  Interferon gamma
IL  Interleukin
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Abstract The complex interaction between cells under-
going transformation and the various stromal and immu-
nological cell components of the tumor microenvironment 
(TME) crucially influences cancer progression and diver-
sification, as well as endowing clinical and prognostic 
significance. The immunosuppression characterizing the 
TME depends on the recruitment and activation of differ-
ent cell types including regulatory T cells, myeloid-derived 
suppressor cells, and tumor-associated macrophages. Less 
considered is the non-cellular component of the TME. 
Here, we focus on the extracellular matrix (ECM) regula-
tory activities that, within the TME, actively contribute to 
many aspects of tumor progression, acting on both tumor 
and immune cells. Particularly, ECM-mediated regulation 
of tumor-associated immunosuppression occurs through 
the modulation of myeloid cell expansion, localization, 
and functional activities. Such regulation is not limited to 
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TAM  Tumor-associated macrophage
TME  Tumor microenvironment
TNF  Tumor necrosis factor
TSP-1  Thrombospondin-1
Relevance of the extracellular matrix in tumors
Although oncogene activation and oncosuppressor gene 
inactivation act as drivers of cancer development, full-
blown tumorigenesis and malignant progression require 
the acquisition of several additional capabilities that enable 
tumor cells to survive, proliferate, invade, metastasize, and 
evade immune recognition and destruction [1]. Further-
more, hematopoietic cells and stromal cells are involved 
in all phases of carcinogenesis and cancer progression and, 
in turn, are themselves modified by the developing cancer. 
The comparison between normal and transformed tissues 
shows a progressive enrichment in inflammatory cells asso-
ciated with variable changes in the stromal composition 
determining the so-called “desmoplastic reaction” that, in 
some cases, configures marked fibrosis characterized by 
excessive extracellular matrix (ECM) deposition as seen in 
some breast cancer histotypes [2].
Within the tumor microenvironment (TME), cancer cells 
and activated fibroblasts in concert with some immune 
cells, such as macrophages, comprise the main source of 
ECM molecules that interpose between the tumor and 
immune cells and can favor or impede their cross-commu-
nication [3–5]. In addition to its expected scaffold proper-
ties, ECM exerts regulatory functions on both tumor and 
stromal cells, suggesting that a comprehensive understand-
ing of the reciprocal cross-talk between the ECM, tumor 
cells, and stromal cells might impact the success of cancer 
therapy programs [6]. For example, collagen deposition 
and stiffness up-regulate integrin signaling, which even-
tually promotes tumor cell survival and proliferation. The 
over-production of lysyl-oxidase (LOX), an enzyme that 
cross-links collagen fibers, promotes extracellular signal-
regulated kinase assembly and phosphoinositide 3 kinase 
signaling, facilitating oncogenic transformation [7].
The key role of ECM in cancer progression is strength-
ened by its prognostic relevance, such as in the case of 
high-grade breast cancers where the ECM-gene profile 
classification correlates with clinical outcome and response 
to therapy [8, 9]. A signature termed ECM3, characterized 
by up-regulation of SPARC, COL1A1, COL5A2, LAMA4, 
COL6A3, and MMP11 genes, delineates the most robust 
cluster with stable tumor partition within 6 independent 
datasets of more than 600 samples, allowing the re-classi-
fication of breast cancers into two groups of ECM3 or non-
ECM3 type [9]. The ECM3 signature characterizes approx-
imately 35% of breast carcinomas including high-grade 
cases, which undergo epithelial to mesenchymal transition 
(EMT) and respond poorly to therapy [10]. Notably, the 
prognostic value of this signature is conserved among all 
breast cancer molecular subtypes suggesting its relevance 
in providing information related to the biology of these 
tumors beyond cancer cell-intrinsic characteristics.
A similar ECM gene cluster, comprising COL1A1, FN1, 
LOX, SPARC, TIMP3, and COL1A2 has been associated 
with the resistance to tamoxifen when administered as a 
first-line therapy inpatients with metastatic breast cancer 
[11]. More recently, a SPARC-driven gene expression sig-
nature obtained from murine models predicted the clinical 
outcome of patients with HER2-enriched breast cancer sub-
types [12]. Notably, signatures enriched in collagen genes 
together with LOX, THBS2, TIMP3, and SPARC have also 
been associated with poor survival after adjuvant chemo-
therapy and with a high hazard of death in ovarian cancer 
[13, 14]. Similarly, in colon cancer, Gene Set Enrichment 
Analysis (GSEA) identified subsets of ECM-encoding 
genes that were strongly correlated with the metastatic 
potential of primary cancers [15].
Other non-epithelial tumors for which a poor clinical 
outcome has been associated with the presence of ECM 
clusters are Hodgkin’s lymphoma (genes: COL18A1, 
COL6A1, MMP2, MMP3, and TIMP1) and some types of 
diffuse large B cell lymphomas (DLBCLs). In DLBCL, 
an ECM-related gene signature fronted by SPARC has 
been reported to be over expressed in cases with a favora-
ble outcome [16]. Notably, in CD5+ DLBCL, a subtype 
of DLBCL with an aggressive disease course, the ECM-
related genes POSTN, SPARC, COL1A1, COL3A1, CSTK, 
MMP9, and LAMB3 were down-regulated [17], suggesting 
that modification leading to either up-or down-regulation 
of ECM genes may have a role in shaping the biology of 
both solid and hematologic malignancies. In this context, 
we have recently reported that the absence of Sparc in auto-
immunity-prone Fas-mutant mice was instrumental to pro-
mote the transformation of CD5+ B-cells toward a malig-
nant lymphoproliferative disease [18].
Interaction between the ECM and the immune 
system
The immune system is the most relevant component of the 
TME governing host-tumor interactions. Active immuno-
suppression depends on the recruitment and activation of 
different cell types including regulatory T cells, myeloid-
derived suppressor cells (MDSCs), and tumor-associated 
macrophages. Similarly to what has been described for 
the ECM, it is possible to predict the clinical outcome 
of a tumor based on the presence and localization of dif-
ferent T lymphocyte subsets [19] or on the expression of 
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immune cell-related gene signatures. Such signatures can 
be identified using tools such as CIBERSORT, a compu-
tational method for inferring leukocyte representation 
in bulk tumors [20]. In particular, a recent application of 
CIBERSORT utilized the expression profile of 22 distinct 
leukocyte subsets as “barcodes”, capable of distinguishing 
different immune cell types, to screen the gene expression 
profiles of 18,000 cancer patients of different tumor types, 
for whom survival data were available [21]. This analysis 
showed that enrichment in T cells, gamma–delta T cells, 
and plasma cells was associated with increased survival in 
all 39 types of cancer analyzed. In contrast, a polymorpho-
nuclear (PMN) leukocyte signature was associated with the 
worst survival in all the histotypes analyzed [21]. Notably, 
as for the ECM signatures, the immune profiles were also 
prognostic across different tumors independently from their 
molecular subtypes, again supporting the idea that such 
signatures are indicative of common biological features 
conserved across different histotypes. Identification of the 
key molecular mechanisms responsible for such common 
biology is, therefore, likely to open to new therapeutic pos-
sibilities that function independently from tumor histotypes 
and molecular subtypes.
In addition, although the ECM signature or the immune 
signature may be independently prognostic, per se, their 
intersection might be even more informative for patient 
selection toward the most appropriate therapeutic regimen. 
In this regard a new method has been described to estimate, 
by gene expression, the tumor infiltration of fibroblasts and 
endothelial cells along with the immune cells, thus offering 
a compelling microenvironment-based patient stratifica-
tion system associated with disease outcome [22]. We also 
observed differential enrichment in immune-related genes 
between non-ECM3 and ECM3 clusters during the process 
of studying the biological mechanism influencing the inter-
action between ECM3 signature and tumor grade. In par-
ticular, high-grade ECM3 and non-ECM3 tumors differed 
in the expression of genes related to immune cell functions, 
with ECM3 tumors deficient for NK, T, and B cell-related 
genes otherwise enriched in their non-ECM3, less aggres-
sive counterparts. Conversely, ECM3 tumors were enriched 
in myeloid cells that, notably, were also localized in close 
contact with tumor cells.
The reduced number of T cells in ECM3+ tumors might 
be explained in several ways. The first points to the role of 
collagen in coordinating T cell migration and activation. 
Collagen fibers can dictate the migratory trajectory of T 
cells and are necessary to stabilize immunological synapses 
whereas an excessively tight ECM negatively affects T cell 
infiltration into the tumor [23]. Another possible explana-
tion for under-represented T cells within ECM3+ tumors 
might depend on the enrichment in immunosuppres-
sive myeloid cells [10]. Tumor-associated myeloid cells 
constitute the main negative regulators of antitumor 
immune responses at the tumor site. A key characteristic of 
these cells is their generation of reactive oxygen (ROS) and 
reactive nitrogen species (RNS) in the tumor microenviron-
ment. ROS and RNS promote post-translational modifica-
tion of chemokines that, as consequence, loose their chem-
otactic activity on T cells [24]. In particular, chemokines 
normally present in the tumor microenvironment including 
CXC12, CCL2, or CCL5 can reduce their binding activity 
to the corresponding receptor on T cells when exposed to 
ROS/RNS-induced post-translational modification [25]. 
For example, the reduced binding affinity of nitrated/nitros-
ylated CCL2 to its receptor CCR2 impairs the homing of 
CD8+ T lymphocytes [25]. Conversely, the nitrated/nitros-
ylated CCL2 does not lose the ability to recruit MDSCs to 
the tumor site, likely owing to a higher expression of CCR2 
on myeloid cells, which may explain the peculiar enrich-
ment in myeloid cells at the expense of T cells that occurs 
in ECM3+ tumors.
Furthermore, defective collagen assembly in Sparc-defi-
cient mice is associated with over-production of myeloid 
cells and/or changes in their activation status in response 
to different stimuli. Indeed, Sparc-deficient mice show an 
increased onset of autoimmune conditions (systemic lupus 
erythematosus) in response to chemically induced (unpub-
lished data) or Fas-driven [18] stimulation through a mech-
anism involving deregulated neutrophil production and 
activation [26].
Overall, these pieces of evidence together suggest that 
myeloid cells may not only serve as a primary sensor of 
ECM modifications but also that they may be relevant for 
the aggressiveness of ECM-rich tumors and, therefore, 
might be targeted for therapeutic purposes. In this context, 
we provided data showing that the EMT features charac-
teristic of ECM3+ tumors can be reverted using immu-
nomodulatory compounds acting on myeloid cells. Nota-
bly, the reversion of the EMT phenotype was associated 
with increased tumor cell proliferation and, therefore, with 
a higher sensitivity to DNA-intercalating drugs, such as 
doxorubicin [10].
Myeloid cell–ECM interactions
We envisage two possible ways for ECM to interfere with 
myeloid cell behavior: acting on the recruitment of myeloid 
cells, and impacting their activation and/or function. As an 
example, in 4T1 murine mammary carcinoma, the presence 
of an ECM gradient associated with the enrichment of mes-
enchymal traits determines a redistribution of myeloid cells 
that concentrate mainly in the collagen-rich mesenchymal 
invasive areas (our unpublished observation). During can-
cer development the intense stromal remodeling recruits 
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macrophages, whose physiological “wound healing” func-
tion is instead converted into pro-tumorigenic activity. 
In mice lacking SPARC, the decreased collagen deposi-
tion allows increased infiltration of M1 macrophages that, 
endowed with interferon gamma (IFNγ) and tumor necrosis 
factor (TNF) production, exhibit anti-tumor properties [4]. 
This suggests that modifications in the ECM may simulta-
neously influence the number and function of immune cells 
within the tumor microenvironment. Consistent with this 
evidence, collagen type I can either promote tumor infil-
tration by immune cells or inhibit macrophage anti-tumor 
activity by blocking M1 polarization and activation [27].
The inhibitory activity of collagens on immune cells is 
likely mediated by specific surface receptors, prototypi-
cally the leukocyte-associated Ig-like receptor (LAIR) that 
is expressed on the surface of most immune cells [28] to 
convey regulatory signals upon collagen binding, an event 
that could contribute to tumor evasion from immunosur-
veillance. We analyzed the expression of LAIR-1 in pre-
viously generated datasets of human immune cells and 
found that LAIR-1 is expressed by almost all leukocytes, 
albeit at different levels. In particular, the expression pat-
tern of LAIR-1 was inversely associated on PMNs along 
with their differentiation status: from higher expression 
on common myeloid progenitors, granulocyte-monocytes 
progenitors, pro-myelocytes, and myelocytes to lower or 
absent expression on PMNs in the bone marrow (BM) or 
in the peripheral blood. Its expression, however, could be 
re-induced in mature PMNs from peripheral tissues upon 
stimulation with inflammatory compounds such as phor-
bol-12-myristate-13-acetate (PMA) or lipopolysaccharide 
([28] and Sangaletti unpublished).
These observations suggest that ECM modification 
might impact the homeostasis of compartments desig-
nated toward myeloid cell generation such as the BM and 
that ECM changes might constitute part of the initiation of 
diseases associated with the loss of quiescence or with the 
abnormal outgrowth of immature myeloid cells, such as 
myelodisplastic syndrome (MDS) and other hematological 
disorders. Additionally, an expansion of immature myeloid 
cells such as detectable in the peripheral blood of patients 
carrying solid tumors might occur in response to similar 
ECM modifications. These expanded myeloid cells exhibit 
the features of promyelocytic cells and are responsible for 
the immune suppression occurring in patients with breast 
and colorectal cancer in correlation with disease progres-
sion [29]. At present, however, it is still not understood 
whether tumor-expanded myeloid cells, such as physio-
logic promyelocytes, retain a profile of LAIR-1 expression 
conducive for response to collagen regulation. Similarly, it 
is not known whether collagens are involved in maintaining 
tumor-associated myeloid cell immunosuppressive pheno-
type, although in the presence of inflammatory stimuli (i.e., 
IFN-γ, TNF) that would be expected to mediate myeloid 
cell activation [30]. Some data on the possible role of colla-
gens in repressing PMN activation have been obtained from 
studying neutrophil extracellular traps (NETs) in the con-
text of autoimmunity, wherein IFN-γ and C5a induction of 
NETs could be inhibited by seeding stimulated PMN onto a 
collagen matrix. Notably, such collagen inhibitory effect is 
prevented in PMNs transiently silenced for LAIR-1 expres-
sion [18].
ECM‑regulation of MDSCs in cancer: a SPARC 
experience
As human high grade ECM3+ breast cancers are char-
acterized by high SPARC expression, enriched myeloid 
cell infiltration, and paucity of T cells, we investigated 
whether SPARC has any functional relation with MDSC 
recruitment and suppressive activities. This was achieved 
by over expressing SPARC in Sparc-deficient or low-
expressing cancer cells. Sparc-transduction in mammary 
tumor cells promoted MDSC expansion, especially of the 
granulocytic subset (ratio 10:1 with the monocytic sub-
set). Myeloid cells expanded by tumors over expressing 
SPARC were functionally different from those expanded by 
Sparc-deficient tumors. The former were more efficient in 
suppressing T cell proliferation and showed higher Stat3, 
interleukin (IL)-6, arginase I, and COX-2 expression. This 
phenotype was reliant upon SPARC-induced Cox-2-regula-
tion of GM-CSF and IL-6 production, two master cytokines 
involved in MDSC differentiation [31]. Consistent with 
this observation, shRNA-mediated SPARC knockdown 
markedly reduced primary tumor growth and completely 
abolished lung colonization of murine 4T1 cells by affect-
ing cell cycle and COX-2-mediated expansion of MDSCs 
[12]. The activation of COX-2 in a SPARC-rich microen-
vironment was related to the higher fibrillar collagen dep-
osition, as collagen represents a direct inducer of COX-2 
[32] (Fig. 1). The relevance of the collagen/COX-2 axis in 
mammary tumorigenesis has been clearly shown in mouse 
models investigating the link between pregnancy and 
ductal carcinoma in situ (DCIS) progression [32]. Accord-
ingly, PyMT/Col1a1tm1jaemice, which carry a mutation in 
the collagenase cleavage site of collagen 1a1, developed 
tumors characterized by dense collagen deposition and 
associated with increased inflammation in comparison to 
PyMT tumors from wild-type mice. COX-2 over expres-
sion was responsible for the robust inflammatory milieu of 
collagen-dense tumors and led to the recruitment of tumor-
associated macrophages (TAMs) and tumor-associated 
neutrophils; a setting that could be reverted by the use of 
celecoxib, a selective COX-2 inhibitor [33]. In addition, the 
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use of celecoxibin our SPARC-hyper-expressing mammary 
tumors reduced MDSC recruitment at the tumor site [10].
Furthermore, the cross-talk between myeloid cells and 
collagens has been elegantly shown in models of skin fibro-
sis in which myeloid-cell-restricted IL-4Rα signaling con-
trols collagen fibril assembly. After mechanical skin injury, 
IL-4Rα signaling, in response to IL-4 and IL-13, coordi-
nates the timely switch of macrophages from the inflamma-
tory to the resolution phase of wound repair, also control-
ling the architecture of collagen fibrils and the biochemistry 
of collagen cross-linking [34]. Myeloid-restricted IL-4Rα-
deficiency has been associated with defective granulation 
tissue formation and wound repair. Similarly, Sparc-defi-
cient mice are characterized by defective wound repair [35] 
where as Sparc-competent M2 macrophages produce colla-
gen and sustain stromatogenesis and metastasis [4, 5].
Overall, these data suggest that SPARC, collagen, COX-
2, and myeloid cells (TAMs and MDSCs) are entwined in 
the tumor microenvironment, where they simultaneously 
support ECM fiber deposition and the instruction of an 
immunosuppressive environment.
Matricellular protein regulation of myelopoiesis
The ECM protein SPARC belongs to the class of matri-
cellular proteins, a group of molecules that exert regula-
tory rather than structural roles within the ECM. Other 
matricellular proteins are thrombospondin 1 and 2, CCN 
family proteins, periostin, osteopontin (OPN), and tenas-
cins. Matricellular proteins share some common features 
including the capacity to interact with ECM structural 
components (i.e., fibrillar collagens), growth factors, and 
proteases and thereby the capacity to interfere with physi-
ological processes such as wound healing and repair [36]. 
Increasing evidence suggests that matricellular proteins 
also share the capacity of regulating myeloid cell behavior 
including their production, recruitment, and activation. In 
particular, these proteins can contribute to the establish-
ment of BM specialized niches regulating the maintenance, 
proliferation, quiescence, and homing of hematopoietic 
stem cells (HSCs) (Fig. 2; Table 1). Different matricellu-
lar proteins have been described to take part in BM HSC 
niches, where they are provided by osteoblasts or BM 
mesenchymal stem cells and subsequently stimulate or 
inhibit the proliferation of HSCs. In this context, SPARC 
deficiency affects HSC function under certain stress condi-
tions, providing survival benefit to SPARC-deficient mice 
treated repeatedly with the chemotherapeutic agent 5-FU 
[37]. This effect was clearly niche-dependent rather than 
cell autonomous. Consistent with this concept we showed 
that SPARC produced by BM stromal cells regulates 
myeloid cell production [38] and B lymphopoiesis [39]. 
Moreover, we reported an enhanced reactive myeloprolif-
erative response to thrombopoietin in the absence of stro-
mal SPARC or from the transplantation of defective  Apcmin 
mutant hematopoietic cells into  Sparc−/− but not wild-type 
recipient BM stroma [38]. Another matricellular protein 
Fig. 1  Matricellular protein 
regulation of tumor-associated 
myelopoiesis. Within the TME 
matricellular proteins have 
been shown to regulate myeloid 
cell behavior and functions 
at different levels. Tumor-
produced SPARC and OPN 
promote MDSC expansion in 
BM and spleen via production 
of VEGF, IL-6, and GM-CSF 
[10, 49]. Tumor-derived SPARC 
promotes the recruitment of 
MDSCs at the tumor site via 
COX-2 and CXCR-4/CXCL12 
axes, where they promote EMT 
and metastases [10]. OPN sus-
tains the recruitment of MDSCs 
at the lung metastatic site where 
they are instrumental for the 
instruction of the metastatic 
niche. In addition, periostin 
takes part in creating the prem-
etastatic niche [47]. Conversely, 
Gr-1-derived TSP-1 has been 
shown to counteract metastases 
development
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that has been described to be a key component of the HSC 
niche and a regulator of primitive hematopoietic progeni-
tor cells is OPN, which is produced by osteoblasts, acts as 
a negative regulator of hematopoiesis, and contributes to 
HSC localization [40]. 
The production SPARC and OPN is often dysregu-
lated in hematopoietic malignancies characterized by 
the altered production of hematopoietic and myeloid 
cells, such as chronic myeloid leukemia (CML) [41], 
MDS [42] and acute myeloid leukemia (AML) [43, 44]. 
Similarly, Tenascin-C is also a critical component of the 
BM microenvironment. In a setting of BM transplanta-
tion, Tenascin-C supports the engraftment of donor BM 
[45] (Fig. 2). Therefore, it appears that a deregulated 
production of myeloid cells at sites in which these cells 
are generated is often associated with the altered pres-
ence of matricellular proteins, suggesting that these pro-
teins may be also involved in regulating extramedullary 
myelopoiesis, which is characterized by the accumulation 
of peripheral MDSCs in secondary lymphoid organs of 
tumor-bearing mice. Additionally, OPN has been shown 
to facilitate the accumulation of splenic MDSCs in mice 
bearing colon cancer by accelerating the differentiation of 
HSCs and heterogeneous myeloid progenitor cells [46]. 
Accordingly, OPN re-expression in OPN-deficient breast 
cancer cells promotes MDSC increase in the peripheral 
blood, spleen, and tumor (Chiodoni unpublished). Simi-
larly, SPARC-expression in breast cancer cells promoted 
myelopoiesis, leading to the expansion of BM, splenic, 
and circulating MDSCs. Notably, matricellular proteins, 
particularly periostin and OPN, also contribute to the 
organization of the MDSC-driven pro-metastatic lung 
niche, albeit with different mechanisms [47–49]. Such 
mechanisms utilize the lectin-type oxidized LDL recep-
tor-1 (LOX-1), which notably identifies human MDSCs 
in cancer patients [50]. In contrast to periostin and OPN, 
Fig. 2  Matricellular protein regulation of the BM niche. Within the 
BM, HSCs and progenitors (CMPs, GMPs) and immature myeloid 
cells (myeloblasts and promyelocytes) express the ECM sensing 
receptor LAIR-1, suggesting that ECM modification might impact the 
homeostasis of compartments delegated to myeloid cell generation 
in the BM. Through their capacity to interact with ECM structural 
components (fibrillar collagens), or through a direct effect on HSCs, 
matricellular proteins, which are mainly produced by BM mesen-
chymal elements, share the capacity to regulate hematopoietic and 
myeloid cell behavior in the BM microenvironment. In such a context 
SPARC, a collagen regulator, has been shown to be involved in con-
trolling HSC quiescence, myeloid cell proliferation, and B cell lym-
phopoiesis. Accordingly, the absence of SPARC was associated with 
the rapid return to quiescence of HSCs in BM transplantation set-
tings, increased myelopoiesis in response to myeloproliferative spurs, 
and to inefficient B cell lymphopoiesis. OPN is another key compo-
nent of the HSC niche; a product of osteoblasts, it acts as negative 
regulator of hematopoiesis and takes part in HSC localization. Simi-
larly to SPARC and OPN, Tenascin-C is a critical component of the 
BM microenvironment. In a setting of BM transplantation, Tenascin-
C supports the engraftment of donor BM cells
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Tsp-1 produced by Gr-1+ myeloid cells contributes to the 
generation of a metastasis-resistant microenvironment 
[51].
Concluding remarks
The imbalance of the tumor immune microenvironment in 
favor of an immunosuppressive milieu rather than toward 
immune activation is generally ascribed to the activity of 
soluble mediators, such as chemokines, cytokines, growth 
factors, and ROS that regulate the recruitment, phenotype, 
and function of immune cells. However, increasing evi-
dence points to the ECM as an active contributor in mold-
ing the tumor-associated immunosuppressive microenvi-
ronment and denotes a role for non-structural matricellular 
proteins in regulating stromal remodeling and immune cell 
recruitment and function in tumors. In this context, mye-
loid cells may be viewed as major sensors of ECM modi-
fications. The parallel finding of ECM-rich and myeloid 
cell-rich gene signatures endorsing independent prognostic 
significance in breast cancer, irrespective of the histotype or 
molecular subtype, opens new prospects related to targeting 
the functional ECM-myeloid cell interface for the develop-
ment of new effective therapeutic agents or strategies.
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